The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Issues
Latest issue
Regular issues
Supplements
PCR Trials
All issues
Articles
Regular articles
Ahead of print
All articles
Topics
Coronary interventions
STEMI
NSTEMI
Stable CAD
Stents and scaffolds
Left main and multivessel disease
Bifurcation lesions
CTO
Other coronary interventions
Interventions for valvular disease
TAVI
Mitral valve replacement and repair
Tricuspid / Pulmonary valve
Other valvular and structural interventions
Interventions for heart failure
Acute heart failure
Chronic heart failure
Peripheral interventions
Below the knee
Abdominal aortic aneurysm
Iliac / Femoral / Popliteal
Other peripheral interventions
Interventions for hypertension
Renal artery angioplasty
Renal denervation
Other hypertension
Interventions for stroke
Carotid stenting
LAA closure
Ischaemic stroke
Other stroke interventions
Services
Subscribe
Advertise
Rights & permissions
Reprint-Eprint
Join our mailing list
About
Overview
Editorial board
Contact us
Author centre
Arnoud van 't Hof
Showing 1-17 of 17 articles
Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
van Ginkel D,
Bor WL,
Dubois CL,
Aarts HM,
Rooijakkers MJ,
van Bergeijk KH,
Rosseel L,
Veenstra L,
De Backer O,
Van Mieghem NM,
van der Kley F,
Wilgenhof A,
Leonora R,
Halim J,
Schotborgh CE,
Barbato E,
Van Der Heyden JA,
Frambach P,
Ferdinande B,
Mylotte D,
Fabris E,
Rensing BJ,
Timmers L,
Swaans MJ,
Brouwer J,
Nijenhuis V,
Peper J,
Vriesendorp PA,
de Laat B,
Ninivaggi M,
Stragier H,
Voskuil M,
IJsselmuiden AJ,
Hermanides RS,
Agostoni P,
van 't Hof A,
Wykrzykowska JJ,
van Royen N,
Delewi R,
ten Berg JM
August 22, 2023 | 10.4244/EIJ-D-23-00206
Letter: Pretreatment with unfractioned heparin in patients undergoing primary PCI: a standard of treatment together with DAPT?
Fabris E,
van 't Hof A
April 24, 2023 | 10.4244/EIJ-D-22-00821
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction
Bor WL,
Zheng K,
Tavenier A,
Gibson CM,
Granger C,
Bentur O,
Lobatto R,
Postma S,
Coller B,
van 't Hof A,
ten Berg JM
August 6, 2021 | 10.4244/EIJ-D-21-00287
Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial
Gargiulo G,
Pasquetto G,
Brugaletta S,
Ferrari F,
Casu G,
Guiducci V,
Dellavalle A,
Liistro F,
Mauro C,
van 't Hof A,
Omerovic E,
Curello S,
de la Torre Hernandez J,
De Servi S,
Belloni F,
Windecker S,
Penzo C,
Colombo A,
da Costa B,
Frigoli E,
Palmieri C,
Nazzaro M,
Falcone C,
Liso A,
Vigna C,
Abate F,
Comeglio M,
Diletti R,
Gabrielli G,
Di Lorenzo E,
Mazzarotto P,
Zimarino M,
Moretti C,
Valgimigli M
June 12, 2019 | 10.4244/EIJ-D-18-00247
Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis
Collet J,
Kerneis M,
Lattuca B,
Yan Y,
Cayla G,
Silvain J,
Lapostolle F,
Ecollan P,
Diallo A,
Vicaut E,
Hamm C,
van 't Hof A,
Montalescot G
September 20, 2018 | 10.4244/EIJ-D-18-00182
One-year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion
Roolvink V,
Ottervanger J,
Ibáñez B,
Dambrink J,
Gosselink M,
Kedhi E,
van Royen N,
Lipsic E,
Remkes W,
Piek J,
Fuster V,
van 't Hof A
August 24, 2018 | 10.4244/EIJ-D-17-00776
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial
Fabris E,
van 't Hof A,
Hamm C,
Lapostolle F,
Lassen JF,
Goodman S,
ten Berg JM,
Bolognese L,
Cequier A,
Chettibi M,
Hammett C,
Huber K,
Janzon M,
Merkely B,
Storey R,
Zeymer U,
Cantor WJ,
Rousseau H,
Vicaut E,
Montalescot G
May 15, 2017 | 10.4244/EIJ-D-16-00965
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial
Hofma S,
Smits PC,
Brouwer J,
Velders M,
van 't Hof A,
Quere M,
de Vries C,
Van Boven A
March 20, 2015 | 10.4244/EIJY15M01_03
Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial
Badings E,
The S,
Dambrink J,
van Wijngaarden J,
Tjeerdsma G,
Rasoul S,
Timmer J,
van der Wielen M,
Lok D,
van 't Hof A
May 21, 2013 | 10.4244/EIJV9I1A9
Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation
De Luca G,
Gibson CM,
Huber K,
Dudek D,
Cutlip D,
Zeymer U,
Gyöngyösi M,
Bellandi F,
Noc M,
Arntz H-R,
Maioli M,
Secco G,
Zorman S,
Gabriel H,
Emre A,
Rakowski T,
van 't Hof A
August 24, 2012 | 10.4244/EIJV8I4A74
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay
Heestermans A,
de Boer M,
van Werkum J,
Mosterd A,
Gosselink A,
Dambrink J,
van Houwelingen K,
Koopmans P,
Hamm C,
Zijlstra F,
ten Berg JM,
van 't Hof A
August 30, 2011 | 10.4244/EIJV7I4A73
Triggering mechanisms of stent thrombosis
Zwart B,
van Werkum J,
Heestermans A,
Kelder J,
Zomer A,
van 't Hof A,
Verheugt F,
ten Berg JM
January 20, 2011
Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial
Timmer J,
ten Berg JM,
Heestermans A,
Dill T,
van Werkum J,
Dambrink J,
Suryapranata H,
Ottervanger J,
Hamm C,
van 't Hof A
August 15, 2010
Incidence, predictors and prognostic importance of bleeding after primary PCI for ST-elevation myocardial infarction
de Boer M,
Hoorntje J,
Gosselink A,
Suryapranata H,
van 't Hof A
May 25, 2010
Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines?
Dambrink J,
Debrauwere J,
van 't Hof A,
Ottervanger J,
Gosselink M,
Hoorntje J,
de Boer M,
Suryapranata H
April 12, 2010
How to set up an effective national primary angioplasty network: lessons learned from five European countries
Knot J,
Widimský P,
Wijns W,
Stenestrand U,
Kristensen S,
van 't Hof A,
Weidinger F,
Janzon M,
Nørgaard B,
Soerensen J,
van de Wetering H,
Thygesen K,
Bergsten P,
Digerfeldt C,
Potgieter A,
Tomer N,
Fajadet J
August 14, 2009
Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design
van 't Hof A,
Hamm C,
Rasoul S,
Gupthan S,
Paolini J,
ten Berg J
November 20, 2007
1
Latest news
AHEAD OF PRINT
Atherectomy in patients with lower extremity PAD
FREE ARTICLE - Mazen S. Albaghdadi et al
September 25, 2023
AHEAD OF PRINT
De-escalation from ticagrelor to clopidogrel in HBR patients
FREE ARTICLE - Min Chul Kim et al
September 19, 2023
NEW ISSUE
State-of-the-Art on Cerebral Embolic Protection; Debating Guided DAPT; 3-Year Outcomes of the EuroCTO Trial; the Myval Device in Non-Calcified Aortic Regurgitation...
New Issue
September 18, 2023
AHEAD OF PRINT
OCT guidance for evaluation and treatment of the long-term consequences of inadequate ostial left circumflex stenting
Free ARTICLE - Dejan Milasinovic et al
September 7, 2023
AHEAD OF PRINT
DCB in large coronary arteries
FREE ARTICLE - Pier Pasquale Leone et al
September 5, 2023
AHEAD OF PRINT
Rationale and design of the DEDICATE-DZHK6 Trial
FREE ARTICLE - Moritz Seiffert et al
September 1, 2023
AHEAD OF PRINT
DWP for TMVR
FREE ARTICLE - Clément Servoz et al
August 29, 2023